Press Releases

 
Press Releases
  Date Title and Summary View
Jan 5, 2016
HAYWARD, Calif., Jan. 05, 2016 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc.  (Nasdaq:ANTH) today announced the appointment of Craig Thompson as President and Chief Operating Officer.  In this role Mr. Thompson will oversee both of Anthera's late stage development programs and commercial preparation efforts.  Anthera also announced the appoin...
Nov 6, 2015
Closed $29 million public offering in July including full exercise of underwriters' option to purchase additional sharesCompleted capsule manufacturing in support of the SOLUTION clinical studyInitiated the SOLUTION clinical study of oral Sollpura™ To regain all Japan rights to blisibimod following termination of Asia partnership HAYWARD, Ca...
Oct 28, 2015
HAYWARD, Calif., Oct. 28, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the Company's attendance at the following healthcare conferences: November 4th, 2015, Mr. Paul F. Truex, President and Chief Executive Officer, will host one-on-one meetings at the 2015 Citi Global Healthcare Conference at the Palac...
Oct 2, 2015
Study to enroll approximately 130 patients with exocrine pancreatic insufficiency More than 50 clinical sites around the United States and Europe are expected to participate Anthera to host reception at the North American Cystic Fibrosis Conference to discuss the SOLUTION program. HAYWARD, Calif., Oct. 2, 2015 (GLOBE...
Sep 14, 2015
Anthera will regain all worldwide rights for blisibimod without cost No patients were enrolled in the BRIGHT-SC study or any other clinical study in Japan Zenyaku is required to continue various funding obligations during the termination period No effect on blisibimod lupus program or Sollpura development program ...
Aug 10, 2015
Reached enrollment target of 400 subjects in Phase 3 CHABLIS-SC1 clinical study with blisibimod Additional data on patient-reported outcomes from Phase 2b PEARL-SC blisibimod clinical study presented at EULAR Increased cash position by an incremental $27 million through public offering in July Addition to the Russell 2...
Jul 30, 2015
HAYWARD, Calif., July 30, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it plans to issue a press release reporting its 2015 second quarter and operational update after the close of the market on Monday, August 10, 2015. About Anthera Pharmaceuticals Anthera Pharmaceuticals is a biopharmac...
Jul 14, 2015
HAYWARD, Calif., July 14, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), today announced that it has completed the previously announced underwritten public offering of 3,833,334 shares of its common stock, offered at a price of $7.50 per share, which includes the exercise in full by the underwriters of their option to purchas...
Jul 9, 2015
HAYWARD, Calif., July 9, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced the pricing of an underwritten public offering of 3,333,334 shares of its common stock, offered at a price of $7.50 per share. The Company estimates that the gross proceeds from the offering, before deducting underwriting discounts and comm...
Jul 8, 2015
HAYWARD, Calif., July 8, 2015 (GLOBE NEWSWIRE) -- Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the ...
Page:
1
... NextLast
= add release to Briefcase
JoomShaper